JP Morgan: Witty Happy To Be 'Promiscuous' To Rebuild GSK's Oncology Presence
This article was originally published in Scrip
Executive Summary
Andrew Witty has taken a lot of flak over the past couple of years as GlaxoSmithKline Plc. lurched from one 'challenge' to another – from the bribery scandal in China and corruption allegations elsewhere, to a string of late-stage product failures, to a less than stellar uptake of its new respiratory franchise. But things are now on a steady footing and the UK-based pharma major is entering a growth phase, if the CEO's comments at the 34th annual JP Morgan Healthcare Conference on Jan. 13 are to betaken at face value.